Article Text

Download PDFPDF

Cyclooxygenase 2 selective inhibitor induced bowel stricture: a case report
  1. O Mir,
  2. R Dhote,
  3. R Scavennec,
  4. S Ropert,
  5. B Christoforov
  1. Department of Internal Medicine, Cochin Hospital, Paris V University, Paris, France
  1. Correspondence to:
    Dr R Dhote
    Service de Médecine Interne 1, Hôpital Cochin, 27 Rue du faubourg, Saint-Jacques 75674, Paris Cedex 14, France; robin.dhotecch.ap-hop-paris.fr

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Several reports have mentioned the role of non-steroidal anti-inflammatory drugs (NSAID) in inducing diaphragm disease and strictures in the small and large bowel.1–3 To our knowledge, there is no such report in patients treated with cyclooxygenase 2 (COX-2) selective inhibitors.

We report the case of a 55 year old man with a past history of axial spondylarthropathy, successfully treated with NSAID from 1975 to 2001; from February 2001, he was treated with celecoxib 400 mg per day for three weeks and then 200 mg/day for two years. He had previous abdominal surgery (appendicectomy) in 1965.

He presented with a 24 hour history of central abdominal pain with persistent vomiting. Clinical and radiological examination confirmed small bowel obstruction. At laparoscopy, a distal ileal obstruction was identified. Coelioscopic laparotomy was then performed, showing evidence of bowel wall stricture; 10 cm of the distal ileum was spared. Macroscopic and microscopic examination of the resected specimen was consistent with a diagnosis of stricture on submucosal ulceration of the small bowel.

This condition is known to be associated with long term use of NSAID. The COX-2 specific inhibitors have been developed in order to improve the gastrointestinal safety of therapy with NSAID. In various clinical trials, COX-2 selective inhibitors have been shown to have similar efficacy to NSAID, with a concomitant association with fewer endoscopic ulcers and serious lower gastrointestinal events.3

This case suggests that COX-2 selective inhibitors can induce bowel wall ulcerations, followed by submucosa fibrosis, which may cause strictures or diaphragm-like disease.

References

Linked Articles